Skip to main content

Rheumatoid Arthritis

    Rheumatology Roundup
    Drs. Jack Cush and Arthur Kavanaugh discuss highlights and key takeaways from ACR 23. This included the following abstracts: 0025 Cannibinoids & pain 1584 TMP/SMX in GPA 0607 CAR-T cells in…
    While there wasn’t much original new programming and research presented on the final day, that didn’t slow the RheumNow faculty from tweeting the noteworthy “Best of ACR” abstracts.  Enjoy these…
    How do we manage difficult discussions about pregnancy in RA?

    Most rheums know that it is important to get pregnancy p
    2 weeks ago
    How do we manage difficult discussions about pregnancy in RA? Most rheums know that it is important to get pregnancy planning right for women of childbearing age living with rheumatic diseases. That is easier said than done, though... https://t.co/cXtqqVv6fp https://t.co/k5afTUKYf8
    L20 at #ACR23

    Phase 3 RCT of #Telitacicept vs. placebo in #RA
    ☝🏻B-cell neutralization by targeting BlyS and APRIL
    2 weeks 1 day ago
    L20 at #ACR23 Phase 3 RCT of #Telitacicept vs. placebo in #RA ☝🏻B-cell neutralization by targeting BlyS and APRIL ✅ better ACR20 and 50 response at W24 ✅ favorable structural response ✅ good safety profile ❓ few seronegative patients A new small molecule to treat #RA? PAJ https://t.co/fyrqAya41e
    #ACR23 #EdLovering presenting on association b/w #RA, #CVD & #Dementia:
    👉🏻CVD is not a signif mediator b/w RA
    2 weeks 1 day ago
    #ACR23 #EdLovering presenting on association b/w #RA, #CVD & #Dementia: 👉🏻CVD is not a signif mediator b/w RA &Dementia 👉🏻 signif synergy b/w RA & CVD on dementia (HR 2.45 vs those w/o RA&CVD) 👉🏻 ⬆️ risk of dementia in RA mostly in people with RA+CVD #Mayoclinicrheumatology https://t.co/5kqs3HAACn
    Impressive and important study supporting safety of TNF inhibitors among patients with RA-ILD. Elegant methods of target
    Impressive and important study supporting safety of TNF inhibitors among patients with RA-ILD. Elegant methods of target trial emulation. Congrats to the authors on plenary presentation! #ACR23 https://t.co/P7keAoOX7M
    Nipocalimab (say it a couple of times) is a FcRn (neonatal Fc receptor) inhibitor. In short promotes degradation of IgG
    2 weeks 1 day ago
    Nipocalimab (say it a couple of times) is a FcRn (neonatal Fc receptor) inhibitor. In short promotes degradation of IgG incl autoantibodies (and investigated in myasthenia). Prof Taylor presents that it might work in CCP high titer RA at #ACR23. #ACRambassador @ACRheum https://t.co/DqlsOv7AVI
    ×